Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice

Andrew L. Feldman, Nicholas P. Restifo, H. Richard Alexander, David L. Bartlett, Patrick Hwu, Prem Seth, Steven K. Libutti

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Gene therapy represents a possible alternative to the chronic delivery of recombinant antiangiogenic proteins to cancer patients. Inducing normal host tissues to produce high circulating levels of these proteins may be more effective than targeting antiangiogenic genes to tumor tissue specifically. Previously reported gene therapy approaches in mice have achieved peak circulating endostatin levels of 8-33 ng/ml. Here we report plasma endostatin levels of 1770 ng/ml after administration of a recombinant adenovirus. Growth of MC38 adenocarcinoma, which is relatively resistant to adenoviral infection, was inhibited by 40%. These findings encourage gene delivery approaches that use the host as a 'factory' to produce high circulating levels of antiangiogenic agents.

Original languageEnglish (US)
Pages (from-to)1503-1506
Number of pages4
JournalCancer Research
Volume60
Issue number6
StatePublished - Mar 15 2000
Externally publishedYes

Fingerprint

Endostatins
Adenoviridae
Genetic Therapy
Angiogenesis Inhibitors
Gene Targeting
Recombinant Proteins
Neoplasms
Adenocarcinoma
Growth
Infection
Genes
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Feldman, A. L., Restifo, N. P., Alexander, H. R., Bartlett, D. L., Hwu, P., Seth, P., & Libutti, S. K. (2000). Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Research, 60(6), 1503-1506.

Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. / Feldman, Andrew L.; Restifo, Nicholas P.; Alexander, H. Richard; Bartlett, David L.; Hwu, Patrick; Seth, Prem; Libutti, Steven K.

In: Cancer Research, Vol. 60, No. 6, 15.03.2000, p. 1503-1506.

Research output: Contribution to journalArticle

Feldman, AL, Restifo, NP, Alexander, HR, Bartlett, DL, Hwu, P, Seth, P & Libutti, SK 2000, 'Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice', Cancer Research, vol. 60, no. 6, pp. 1503-1506.
Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Research. 2000 Mar 15;60(6):1503-1506.
Feldman, Andrew L. ; Restifo, Nicholas P. ; Alexander, H. Richard ; Bartlett, David L. ; Hwu, Patrick ; Seth, Prem ; Libutti, Steven K. / Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. In: Cancer Research. 2000 ; Vol. 60, No. 6. pp. 1503-1506.
@article{4f02ef7befc04f75baddca719c1e13c5,
title = "Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice",
abstract = "Gene therapy represents a possible alternative to the chronic delivery of recombinant antiangiogenic proteins to cancer patients. Inducing normal host tissues to produce high circulating levels of these proteins may be more effective than targeting antiangiogenic genes to tumor tissue specifically. Previously reported gene therapy approaches in mice have achieved peak circulating endostatin levels of 8-33 ng/ml. Here we report plasma endostatin levels of 1770 ng/ml after administration of a recombinant adenovirus. Growth of MC38 adenocarcinoma, which is relatively resistant to adenoviral infection, was inhibited by 40{\%}. These findings encourage gene delivery approaches that use the host as a 'factory' to produce high circulating levels of antiangiogenic agents.",
author = "Feldman, {Andrew L.} and Restifo, {Nicholas P.} and Alexander, {H. Richard} and Bartlett, {David L.} and Patrick Hwu and Prem Seth and Libutti, {Steven K.}",
year = "2000",
month = "3",
day = "15",
language = "English (US)",
volume = "60",
pages = "1503--1506",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice

AU - Feldman, Andrew L.

AU - Restifo, Nicholas P.

AU - Alexander, H. Richard

AU - Bartlett, David L.

AU - Hwu, Patrick

AU - Seth, Prem

AU - Libutti, Steven K.

PY - 2000/3/15

Y1 - 2000/3/15

N2 - Gene therapy represents a possible alternative to the chronic delivery of recombinant antiangiogenic proteins to cancer patients. Inducing normal host tissues to produce high circulating levels of these proteins may be more effective than targeting antiangiogenic genes to tumor tissue specifically. Previously reported gene therapy approaches in mice have achieved peak circulating endostatin levels of 8-33 ng/ml. Here we report plasma endostatin levels of 1770 ng/ml after administration of a recombinant adenovirus. Growth of MC38 adenocarcinoma, which is relatively resistant to adenoviral infection, was inhibited by 40%. These findings encourage gene delivery approaches that use the host as a 'factory' to produce high circulating levels of antiangiogenic agents.

AB - Gene therapy represents a possible alternative to the chronic delivery of recombinant antiangiogenic proteins to cancer patients. Inducing normal host tissues to produce high circulating levels of these proteins may be more effective than targeting antiangiogenic genes to tumor tissue specifically. Previously reported gene therapy approaches in mice have achieved peak circulating endostatin levels of 8-33 ng/ml. Here we report plasma endostatin levels of 1770 ng/ml after administration of a recombinant adenovirus. Growth of MC38 adenocarcinoma, which is relatively resistant to adenoviral infection, was inhibited by 40%. These findings encourage gene delivery approaches that use the host as a 'factory' to produce high circulating levels of antiangiogenic agents.

UR - http://www.scopus.com/inward/record.url?scp=0034654555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034654555&partnerID=8YFLogxK

M3 - Article

C2 - 10749112

AN - SCOPUS:0034654555

VL - 60

SP - 1503

EP - 1506

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 6

ER -